164 related articles for article (PubMed ID: 32936345)
21. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
22. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
23. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
[TBL] [Abstract][Full Text] [Related]
25. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
Manriquez J; Alsina-Gibert M
Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
[TBL] [Abstract][Full Text] [Related]
26. Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
Roblin X; Genin C; Nancey S; Williet N; Veyrard P; Boschetti G; Phelip JM; Berger AE; Killian M; Waeckel L; Flourie B; Paul S
Inflamm Bowel Dis; 2022 May; 28(5):720-727. PubMed ID: 34405867
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
[TBL] [Abstract][Full Text] [Related]
29. Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
Anjie SI; Hanzel J; Gecse KB; D'Haens GR; Brandse JF
Scand J Gastroenterol; 2024; 59(2):169-175. PubMed ID: 37961895
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
32. Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
Bond A; Dodd S; Fisher G; Skouras T; Subramanian S
Scand J Gastroenterol; 2017 Feb; 52(2):204-208. PubMed ID: 27797269
[TBL] [Abstract][Full Text] [Related]
33. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
[TBL] [Abstract][Full Text] [Related]
34. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
35. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
Hinojosa J; Muñoz F; Martínez-Romero GJ
Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560
[TBL] [Abstract][Full Text] [Related]
36. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
37. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
Yanai S; Shinzaki S; Matsuoka K; Mizuno S; Iijima H; Naka T; Kanai T; Matsumoto T
Digestion; 2021; 102(6):929-937. PubMed ID: 34350873
[TBL] [Abstract][Full Text] [Related]
38. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
[TBL] [Abstract][Full Text] [Related]
39. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
[TBL] [Abstract][Full Text] [Related]
40. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
Sandborn WJ; Colombel JF; Schreiber S; Plevy SE; Pollack PF; Robinson AM; Chao J; Mulani P
Inflamm Bowel Dis; 2011 Jan; 17(1):141-51. PubMed ID: 20848500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
